How are the Premier's Awards helping cancer researchers?
2 May 2019
The Premier’s Awards not only recognise the state’s top cancer researchers but also propels their work to greater heights.
Hear from the 2017 winners and find out how it is influencing their work:
Melanoma Translational Research Team
– Wildfire Highly Cited Publication Award
The award is allowing Professor Rizos’ team to extend their research into regulating melanoma gene expression and its role in the response of melanoma to immunotherapy.
Melanoma Institute Australia
– Excellence in Translational Cancer Research Award
The award is supporting a plethora of Melanoma Institute Australia research projects that made headlines around the world. These include discovering the specific mechanisms behind immune-mediated equilibrium
Professor Scolyer and Professor Long won major awards at the 2018
– Outstanding Cancer Researcher of the Year Award
Professor Kefford’s is commissioning a tailor-made, melanoma-specific gene mutation panel for DNA sequencing machinery in their laboratory. The award is enabling his team to extend their research into regulating melanoma gene expression and its role in the response of melanoma to immunotherapy.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
We have a winner!